CS
RARX

Candriam SCA’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Candriam SCA’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-99,523
Closed -$4.57M – 899
2020
Q1 		$4.57M Hold
99,523
– – 0.05% 372
2019
Q4 		$4.67M Sell
99,523
-1,128,477
-92% -$49.9M 0.05% 379
2019
Q3 		$29M Buy
1,228,000
+50,000
+4% +$1.48M 0.38% 51
2019
Q2 		$35.3M Buy
1,178,000
+154,000
+15% +$3.53M 0.44% 44
2019
Q1 		$22.9M Buy
1,024,000
+145,000
+16% +$3.12M 0.29% 74
2018
Q4 		$16M Buy
879,000
+444,000
+102% +$6.97M 0.25% 91
2018
Q3 		$7.87M Buy
435,000
+285,000
+190% +$3.38M 0.1% 226
2018
Q2 		$1.49M Sell
150,000
-1,000
-0.7% -$6.91K 0.02% 536
2018
Q1 		$802K Hold
151,000
– – 0.01% 624
2017
Q4 		$1.28M Buy
151,000
+35,000
+30% +$430K 0.02% 534
2017
Q3 		$1.69M Buy
116,000
+35,000
+43% +$529K 0.03% 485
2017
Q2 		$1.52M Buy
+81,000
New +$1.83M 0.03% 510

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Candriam SCA's RARX Position: Q2 2020 in Review

Candriam SCA sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 99,523 shares — an estimated $4.57M sold.

Candriam SCA first reported a position in RARX in Q2 2017 and held it in 12 quarters. The position peaked at $35.3M in Q2 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Candriam SCA reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Candriam SCA sold 99,523 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $4.57M.
  • Candriam SCA first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 12 quarters.
  • Candriam SCA's Ra Pharmaceuticals, Inc. Common Stock position peaked at $35.3M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.